Published in Surgery Litigation and Law Weekly, January 20th, 2012
Dear Fellow Shareholders,
The last year has been remarkable for Medistem: new investors, new collaborators, and an FDA approval. The FDA approval is for a 15 patient study investigating the safety and therapeutic effects of company's universal donor stem cell product, the Endometrial Regenerative Cell (ERC) in patients with critical limb ischemia. The trial is led by Harvard-trained Dr. Michael Murphy from Indiana University, who was the first physician in the US to use stem cells for treatment of this condition. Dr. Murphy is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly